Literature DB >> 33557064

Clinical Outcomes of Radical Surgery and Antimicrobial Agents in Vascular Pythiosis: A Multicenter Prospective Study.

Pattama Torvorapanit1,2, Nipat Chuleerarux1, Rongpong Plongla1,2, Navaporn Worasilchai3, Kasama Manothummetha1, Achitpol Thongkam1, Nattapong Langsiri1, Jaruwan Diewsurin4, Prasopchai Kongsakpaisan5, Ratiporn Bansong6, Nuttapon Susaengrat7, Watchara Wattanasoontornsakul8, Ariya Chindamporn1, Nitipong Permpalung1,9.   

Abstract

Vascular pythiosis is a rare, neglected, life-threatening disease with mortality of 100% in patients with incomplete surgical resection or patients with persistently elevated serum β-d-glucan (BDG). The study was conducted to understand the clinical outcomes of new treatment protocols and potential use of erythrocyte sedimentation rate (ESR) and c-reactive protein (CRP) as alternative monitoring tools, given recent favorable minimum inhibitory concentrations (MICs) of antibacterial agents and prohibitive cost of serum BDG in Thailand. A prospective cohort study of patients with vascular pythiosis was conducted between February 2019 and August 2020. After diagnosis, patients were followed at 0.5, 1, 1.5, 3, and 6 months. Descriptive statistics, Spearman's correlation coefficient, and general linear model for longitudinal data were used. Amongst the cohort of ten vascular pythiosis patients, four had residual disease after surgery. Among four with residual disease, one developed disseminated disease and died, one developed relapse disease requiring surgery, and two were successfully managed with antimicrobial agents. The spearman's correlation coefficients between BDG and ESR, and between BDG and CRP in patients without relapse or disseminated disease were 0.65 and 0.60, respectively. Tetracyclines and macrolides had most favorable minimum inhibitory concentrations and synergistic effects were observed in combinations of these two antibiotic classes. Adjunctive use of azithromycin and doxycycline preliminarily improved survival in vascular pythiosis patients with residual disease. Further studies are needed to understand the trends of ESR and CRP in this population.

Entities:  

Keywords:  CRP; ESR; P. insidiosum; human pythiosis; vascular pythiosis; β-d-glucan

Year:  2021        PMID: 33557064      PMCID: PMC7913857          DOI: 10.3390/jof7020114

Source DB:  PubMed          Journal:  J Fungi (Basel)        ISSN: 2309-608X


  38 in total

1.  Clinical outcomes in ocular pythiosis patients treated with a combination therapy protocol in Thailand: A prospective study.

Authors:  Nitipong Permpalung; Navaporn Worasilchai; Kasama Manothummetha; Pattama Torvorapanit; Kitiya Ratanawongphaibul; Nipat Chuleerarux; Rongpong Plongla; Ariya Chindamporn
Journal:  Med Mycol       Date:  2019-11-01       Impact factor: 4.076

2.  Systemic Pythium insidiosum in a pediatric burn patient.

Authors:  Dori M Franco; Judith F Aronson; Hal K Hawkins; James J Gallagher; Leonel Mendoza; Michael R McGinnis; Natalie Williams-Bouyer
Journal:  Burns       Date:  2009-10-28       Impact factor: 2.744

3.  Successful medical therapy for deeply invasive facial infection due to Pythium insidiosum in a child.

Authors:  J L Shenep; B K English; L Kaufman; T A Pearson; J W Thompson; R A Kaufman; G Frisch; M G Rinaldi
Journal:  Clin Infect Dis       Date:  1998-12       Impact factor: 9.079

4.  In Vitro Susceptibility of Thai Pythium insidiosum Isolates to Antibacterial Agents.

Authors:  Navaporn Worasilchai; Ariya Chindamporn; Rongpong Plongla; Pattama Torvorapanit; Kasama Manothummetha; Nipat Chuleerarux; Nitipong Permpalung
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

5.  In vitro and in vivo susceptibility of two-drug and three-drug combinations of terbinafine, itraconazole, caspofungin, ibuprofen and fluvastatin against Pythium insidiosum.

Authors:  Juliana S Argenta; Sydney H Alves; Flávio Silveira; Grazieli Maboni; Régis A Zanette; Ayrton S Cavalheiro; Patrique L Pereira; Daniela I B Pereira; Elisa S V Sallis; Luciana Pötter; Janio M Santurio; Laerte Ferreiro
Journal:  Vet Microbiol       Date:  2011-12-09       Impact factor: 3.293

6.  High-resolution melting analysis: A novel approach for clade differentiation in Pythium insidiosum and pythiosis.

Authors:  Navaporn Worasilchai; Nitipong Permpalung; Ariya Chindamporn
Journal:  Med Mycol       Date:  2018-10-01       Impact factor: 4.076

7.  Decreased concentrations of tumor necrosis factor-alpha in supernatants of monocytes from homozygotes for hereditary hemochromatosis.

Authors:  V R Gordeuk; S Ballou; G Lozanski; G M Brittenham
Journal:  Blood       Date:  1992-04-01       Impact factor: 22.113

8.  Adjunctive antibacterial agents as a salvage therapy in relapsed vascular pythiosis patients.

Authors:  Nuttapon Susaengrat; Pattama Torvorapanit; Rongpong Plongla; Nipat Chuleerarux; Kasama Manothummetha; Jarruprot Tuangsirisup; Navaporn Worasilchai; Ariya Chindamporn; Nitipong Permpalung
Journal:  Int J Infect Dis       Date:  2019-09-04       Impact factor: 3.623

9.  In Vitro and In Vivo Antimicrobial Activities of Minocycline in Combination with Azithromycin, Clarithromycin, or Tigecycline against Pythium insidiosum.

Authors:  Francielli P K Jesus; Érico S Loreto; Laerte Ferreiro; Sydney H Alves; David Driemeier; Suyene O Souza; Raqueli T França; Sonia T A Lopes; Maiara B Pilotto; Aline Ludwig; Maria I Azevedo; Tatiana C Ribeiro; Juliana S M Tondolo; Janio M Santurio
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

Review 10.  Identifying serious causes of back pain: cancer, infection, fracture.

Authors:  Krzysztof Siemionow; Michael Steinmetz; Gordon Bell; Hakan Ilaslan; Robert F McLain
Journal:  Cleve Clin J Med       Date:  2008-08       Impact factor: 2.321

View more
  1 in total

1.  Global Distribution and Clinical Features of Pythiosis in Humans and Animals.

Authors:  Hanna Yolanda; Theerapong Krajaejun
Journal:  J Fungi (Basel)       Date:  2022-02-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.